Sulfadiazine zinc ointment

For external use, it can replace silver sulfadiazine and promote wound healing and has antibacterial and astringent effects.

Sulfadiazine Zinc

This product is a white or yellow ointment.

Used for fresh wounds caused by burns and trauma, chronic ulcer wounds and abscess cavities.

After cleaning the wound with disinfectant solution, this product can be applied directly to the wound and then covered with sterile gauze. Alternatively, the ointment can be applied on sterile gauze, applied to the wound, and then covered with sterile gauze. Alternatively, the sterile gauze coated with ointment can be directly placed into the abscess cavity to drain the pus. The amount of ointment used depends on the size of the wound and the infection situation. The daily dosage should not exceed 500g.

After using this product, some patients may develop contact dermatitis, which manifests as transient pain and rash. After local absorption, this product may occasionally cause various adverse reactions similar to those of systemic application of sulfonamides, including: 1. Allergic reactions are more common, which may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis and bullous epidermolysis atrophic dermatitis may occur; there are also serum sickness-like reactions such as photosensitivity, drug fever, joint and muscle pain, fever, etc. 2. Neutropenia or deficiency, thrombocytopenia and aplastic anemia. Patients may show sore throat, fever, pallor and bleeding tendency. 3. Hemolytic anemia and hemoglobinuria. This is easy to occur in patients who lack glucose-6-phosphate dehydrogenase after using sulfonamides, and is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because sulfonamides compete with bilirubin for protein binding sites, it can cause an increase in free bilirubin. Neonates have imperfect liver function, so they are more likely to develop hyperbilirubinemia and neonatal jaundice. Kernicterus may occasionally occur. 5. Liver damage. Jaundice and decreased liver function may occur, and in severe cases, acute liver necrosis may occur. 6. Kidney damage. Crystalluria, hematuria, and tubular urine may occur. Occasionally, patients may develop serious adverse reactions such as interstitial nephritis or renal tubular necrosis. 7. Nausea, vomiting, decreased appetite, diarrhea, headache, fatigue, etc. Generally, the symptoms are mild and do not affect continued medication. Occasionally, patients develop Clostridium difficile enteritis, and the drug should be discontinued at this time. 8. Occasionally, thyroid enlargement and hypofunction occur. 9. Central nervous system toxicity may occasionally occur, manifested as mental confusion, disorientation, hallucinations, euphoria or depression. Once it occurs, the drug should be discontinued immediately.

1. It is contraindicated for those who are allergic to sulfonamide drugs. 2. It is contraindicated for pregnant women and breastfeeding women. 3. It is contraindicated for infants under 2 months old. 4. It is contraindicated for those with poor liver and kidney function.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

This product can be absorbed locally, and its drug interactions are the same as those of systemic sulfonamides. 1. When used in combination with urine alkalinizing drugs, the solubility of this product in alkaline urine can be increased, resulting in increased excretion. 2. It cannot be used in combination with para-aminobenzoic acid, which can replace this product for bacterial uptake, and the two are mutually antagonistic. It is also not suitable to be used in combination with local anesthetics containing para-aminobenzoyl such as procaine, benzocaine, tetracaine, etc. 3. When used in combination with oral anticoagulants, oral hypoglycemic drugs, methotrexate, phenytoin sodium and thiopental sodium, the above drugs need to be adjusted in dose, because this product can replace the protein binding sites of these drugs, or inhibit their metabolism, resulting in prolonged drug action time or toxicity. 4. When used in combination with bone marrow suppressive drugs, the potential adverse reactions of such drugs may be enhanced. If there is an indication for the simultaneous use of two types of drugs, possible toxic reactions should be closely observed. 5. Long-term use with contraceptives (estrogens) can reduce the reliability of contraception and increase the chance of extramenstrual bleeding. 6. When used in combination with thrombolytic drugs, its potential toxic effects may be increased. 7. When used in combination with hepatotoxic drugs, it may cause an increase in the incidence of hepatotoxicity. Such patients, especially those who have been taking the drug for a long time and have a history of liver disease, should be closely monitored. 8. When used in combination with photosensitizing drugs, photosensitivity may be additive. 9. Patients receiving this product have an increased need for vitamin K. 10. It should not be used in combination with methenamine, because methenamine can decompose in acidic urine to produce formaldehyde, which can form insoluble precipitates with this product, increasing the risk of crystalluria. 11. This product can replace the plasma protein binding site of phenylbutazone, and the combination of the two can increase the effect of phenylbutazone. 12. Because this product may interfere with the bactericidal effect of penicillins, it is best to avoid using it at the same time with such drugs. 13. When sulfinpyrazone is used in combination with this product, the secretion of this product from the renal tubules can be reduced, and its blood concentration will increase and last for a long time, thus producing toxic reactions. Therefore, the dose of this product may need to be adjusted during or after the use of sulfinpyrazone.

Protect from light, seal tightly and store in a cool place.

5%

24 months

Henan Quanyu Pharmaceutical Co., Ltd.

• Founded in:

  2004-12-29

• Address:

  Longyuan Road, Neixiang Industrial Park

• Tax NO.:

  914113007374094253

• Registered Funds:

  77 million yuan

• Website:

  Log in to view

• Email:

  Log in to view